Tonix Pharmaceuticals Valuation
| TNXP Stock | USD 8.43 0.38 4.72% |
At this time, the company appears to be overvalued. Tonix Pharmaceuticals has a current Real Value of $7.17 per share. The regular price of the company is $8.43. Our model measures the value of Tonix Pharmaceuticals from inspecting the company fundamentals such as Shares Owned By Insiders of 0.06 %, current valuation of 29.49 M, and Return On Equity of -1.39 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Tonix Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Tonix Pharmaceuticals is based on 3 months time horizon. Increasing Tonix Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Tonix Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 8.43, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.43 | Real 7.17 | Hype 8.43 | Naive 5.92 |
The intrinsic value of Tonix Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tonix Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tonix Pharmaceuticals Holding helps investors to forecast how Tonix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tonix Pharmaceuticals more accurately as focusing exclusively on Tonix Pharmaceuticals' fundamentals will not take into account other important factors: Tonix Pharmaceuticals Total Value Analysis
Tonix Pharmaceuticals Holding is at this time anticipated to have valuation of 29.49 M with market capitalization of 45 M, debt of 9.81 M, and cash on hands of 145.48 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Tonix Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.49 M | 45 M | 9.81 M | 145.48 M |
Tonix Pharmaceuticals Investor Information
The company has price-to-book ratio of 0.66. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tonix Pharmaceuticals recorded a loss per share of 8039.0. The entity last dividend was issued on the 1st of November 2019. The firm had 1:100 split on the 5th of February 2025. Based on the key indicators related to Tonix Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Tonix Pharmaceuticals Holding is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Tonix Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Tonix Pharmaceuticals has an asset utilization ratio of 5.03 percent. This connotes that the Company is making $0.0503 for each dollar of assets. An increasing asset utilization means that Tonix Pharmaceuticals Holding is more efficient with each dollar of assets it utilizes for everyday operations.Tonix Pharmaceuticals Ownership Allocation
The market capitalization of Tonix Pharmaceuticals is $45 Million. About 96.62 % of Tonix Pharmaceuticals outstanding shares are held by general public with 0.056 (%) owned by insiders and only 3.32 % by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Tonix Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 7.77 M. Net Loss for the year was (116.66 M) with profit before overhead, payroll, taxes, and interest of 2.34 M.About Tonix Pharmaceuticals Valuation
The stock valuation mechanism determines Tonix Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Tonix Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Tonix Pharmaceuticals. We calculate exposure to Tonix Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tonix Pharmaceuticals's related companies.Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Tonix Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.
Tonix Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Tonix Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 532.5 K |
Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.